ZA200710000B - Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor - Google Patents

Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Info

Publication number
ZA200710000B
ZA200710000B ZA200710000A ZA200710000A ZA200710000B ZA 200710000 B ZA200710000 B ZA 200710000B ZA 200710000 A ZA200710000 A ZA 200710000A ZA 200710000 A ZA200710000 A ZA 200710000A ZA 200710000 B ZA200710000 B ZA 200710000B
Authority
ZA
South Africa
Prior art keywords
nanoparticulate
controlled release
platelet aggregation
release compositions
aggregation inhibitor
Prior art date
Application number
ZA200710000A
Other languages
English (en)
Inventor
Scott Jenkins
Paul Stark
Niall M M Fanning
Gary Liversidge
John G Devane
Singh Gurvinder Rekhi
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of ZA200710000B publication Critical patent/ZA200710000B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200710000A 2005-05-23 2007-11-20 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor ZA200710000B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68362005P 2005-05-23 2005-05-23

Publications (1)

Publication Number Publication Date
ZA200710000B true ZA200710000B (en) 2009-12-30

Family

ID=39153748

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710000A ZA200710000B (en) 2005-05-23 2007-11-20 Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Country Status (12)

Country Link
US (1) US20090297596A1 (enExample)
EP (1) EP1937218A2 (enExample)
JP (1) JP2008545808A (enExample)
KR (1) KR20080047509A (enExample)
CN (1) CN101287451A (enExample)
BR (1) BRPI0609982A2 (enExample)
CA (1) CA2611506A1 (enExample)
EA (1) EA200702595A1 (enExample)
IL (1) IL187567A0 (enExample)
NO (1) NO20076588L (enExample)
WO (1) WO2008030209A2 (enExample)
ZA (1) ZA200710000B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775819B2 (en) 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
MX2014015310A (es) * 2012-06-15 2015-07-06 Found Biomedical Res & Innov Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve.
TWI697337B (zh) * 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法
CN103980326A (zh) * 2014-05-05 2014-08-13 珀莱雅化妆品股份有限公司 一种超临界co2反胶束萃取红景天苷的制备方法
KR101869406B1 (ko) * 2015-11-25 2018-07-24 한국유나이티드제약 주식회사 방출제어형 경질캡슐 제제
CN112592379B (zh) * 2020-12-18 2021-11-16 广东药科大学 一种β-D-葡萄糖短链脂肪酸酯化合物及其制备方法和应用
CN114796217B (zh) * 2021-01-29 2025-01-24 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
CN117982677B (zh) * 2024-02-05 2025-09-09 沈阳药科大学 背载血小板激活抑制剂纳米粒的工程化血小板及其制备方法及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU677783B2 (en) * 1992-06-10 1997-05-08 Elan Pharma International Limited Surface modified nsaid nanoparticles
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
JP4641696B2 (ja) * 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
EP1267946A4 (en) * 2000-02-28 2008-07-02 Genesegues Inc SYSTEM AND METHOD FOR ENCAPSULATING NANOCAPSULES
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6573382B2 (en) * 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations

Also Published As

Publication number Publication date
NO20076588L (no) 2008-02-20
CA2611506A1 (en) 2006-11-23
BRPI0609982A2 (pt) 2010-05-18
EP1937218A2 (en) 2008-07-02
EA200702595A1 (ru) 2008-12-30
WO2008030209A3 (en) 2008-07-03
US20090297596A1 (en) 2009-12-03
IL187567A0 (en) 2011-08-01
KR20080047509A (ko) 2008-05-29
CN101287451A (zh) 2008-10-15
JP2008545808A (ja) 2008-12-18
WO2008030209A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
IL187567A0 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
SG138592A1 (en) Nanoparticulate and controlled release compositions comprising cephalosporin
ZA200710697B (en) Formulation of a thienopyridine platelet aggregation inhibitor
EP2062871A4 (en) OLIGOANILINE COMPOUND AND ITS USE
IL186469A0 (en) Nanoparticulate and controlled release compositions comprising cyclosporine
IL244442A0 (en) Compounds of converted acylanilides and their use
ZA200810098B (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
ZA200809971B (en) Nanoparticulate posaconazole formulations
LT2957278T (lt) Stabili kompozicija, apimanti pthrp ir jos panaudojimas
IL186028A0 (en) Reclosable package
IL196065A0 (en) Compositions comrising nanoparticulate naproxen and controlled release hydrocodone
IL187431A0 (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
ZA200903401B (en) The uses of the carboxy-amido-triazole compounds and salts thereof
ZA200802436B (en) Composition comprising a NSAID and paracetamol
IL188093A0 (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
IL228986A0 (en) A preparation that inhibits the aggregation of blood platelets
GB0720887D0 (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
ZA200710715B (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
HK1119943A (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
HK1116690A (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
HK1117064A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
GB0609555D0 (en) Packaging 26
GB0608705D0 (en) Packaging 27
GB0609559D0 (en) Packaging 30
GB0619092D0 (en) Packaging 32